Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human hsp110-gp100 chaperone complex vaccine
- Development stage
- Phase 1
- Lead developer
- Roswell Park Comprehensive Cancer Center
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
Recombinant human hsp110-gp100 chaperone complex vaccine is an investigational, fully recombinant therapeutic cancer vaccine developed by Roswell Park Comprehensive Cancer Center for advanced melanoma. It consists of recombinant human heat shock protein 110 complexed with the full-length human melanoma differentiation antigen gp100. The Hsp110 chaperone component promotes antigen delivery and immune stimulation, supporting gp100-specific interferon-gamma production and cytotoxic CD8-positive T-cell responses directed against gp100-expressing melanoma cells. In a Phase Ib dose-escalation study in previously treated unresectable stage IIIB/C or IV melanoma, intradermal administration showed minimal toxicity and limited clinical activity at lower dose levels. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35254331/))
- Other names
- recombinant Hsp110-gp100 vaccinerecombinant hsp110-gp100 chaperone complex vaccineHsp110-gp100 chaperone complex vaccineHsp-110-gp100 chaperone complex vaccineHsp 110-gp100 chaperone complex vaccine
02
Targets
PMEL (Melanocyte Protein PMEL)HSP110 (Heat shock protein 110)
Beyond the preview
Go deeper on recombinant human hsp110-gp100 chaperone complex vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human hsp110-gp100 chaperone complex vaccine.